Showing 1861-1870 of 2494 results for "".
- Samsung Bioepis Presents Data from its Ophthalmology Biosimilar Portfolio at AAO 2022 Annual Meetinghttps://modernod.com/news/samsung-bioepis-presents-data-from-its-ophthalmology-biosimilar-portfolio-at-aao-2022-annual-meeting/2481121/Samsung Bioepis announced that three scientific abstracts relating to its ophthalmology biosimilar portfolio will be presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held from September 30 to October 3, 2022 in Chicago. The phase 3 study on SB15, a
- Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Devicehttps://modernod.com/news/olympic-ophthalmics-announces-fda-clearance-and-availability-of-its-next-generation-itear100-neurostimulation-device-expanded-patent-portfolio-and-further-clinical-studies/2480737/Olympic Ophthalmics announced that the FDA has granted 510(K) clearence for its second-generation iTEAR100 device, a prescription neuromodulation therapy to acutely increase tear production in adult patients over a 30-day period. The second-generation device is a connected device o
- MeiraGTx Receives Clinical Development Milestone Payment from Janssenhttps://modernod.com/news/meiragtx-receives-clinical-development-milestone-payment-from-janssen/2480599/MeiraGTx Holdings announced that it has received a $30 million payment from Johnson & Johnson's Janssen Pharmaceuticals for a clinical milestone in the phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinit
- TearClear Files IND Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solutionhttps://modernod.com/news/tearclear-files-ind-application-to-begin-its-clinical-trial-for-tc-002-latanoprost-ophthalmic-solution/2479495/TearClear has filed an investigational new drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution 0.005%. Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderat
- Oyster Point Pharma Names Donald Santel as Chairman of the Board of Directorshttps://modernod.com/news/oyster-point-pharma-names-donald-santel-as-chairman-of-the-board-of-directors/2479427/Oyster Point Pharma announced the appointment of Donald Santel as non-executive Chairperson and a Director of the company and a member of the Compensation Committee. Mr. Santel joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, MD, steps down as Ch
- Horizon Therapeutics Partners With Olympic Gold Medalist Gail Devers to Raise Awareness of Graves’ Disease and Symptoms of Thyroid Eye Disease (TED)https://modernod.com/news/horizon-therapeutics-partners-with-olympic-goldmmedalist-gail-devers-to-raise-awareness-of-graves-disease-and-symptoms-of-thyroid-eye-disease-ted/2479357/For Graves’ Disease Awareness Month in July, Horizon Therapeutics is teaming up with track star and three-time Olympic gold medalist Gail Devers, who has been living with Graves’ disease and symptoms of Thyroid Eye Disease (TED) for more than 30 years. Horizon and Ms. Devers are collaborating wit
- AcuFocus Appoints Industry Leader John Garland as Global Vice President of Saleshttps://modernod.com/news/acufocus-appoints-industry-leader-john-garland-as-global-vice-president-of-sales/2479257/AcuFocus announced that it has appointed John Garland as its Global Vice President of Sales. In his new role, he will be responsible for global sales strategy and will focus initially on building the US sales field team. Mr. Garland brings more than 30 years of experience to the position w
- Heru Series A Funding Accelerates Cloud and AI-Enabled Wearable Vision Diagnosis and Therapyhttps://modernod.com/news/heru-series-a-funding-accelerates-cloud-and-ai-enabled-wearable-vision-diagnosis-and-therapy/2479231/Heru, developer of wearable AI-powered vision diagnostics and augmentation software, closed its Series A financing of $30 million to advance the company’s eye diagnostic and vision correction technology platform. Originating as a spinout from Bascom Palmer Eye Institute, the Series A follo
- Johnson & Johnson Vision Presents New Myopia, Cataract, Refractive, and Meibomian Gland Dysfunction Data at ARVO 2021https://modernod.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/Johnson & Johnson Vision will present nearly 30 posters and papers of research data on myopia, IOL, phacoemulsification, refractive, and meibomian gland dysfunction at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. This year’s premier vision research meet
- Ocular Therapeutix Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients With Glaucomahttps://modernod.com/news/ocular-therapeutix-presents-interim-topline-data-from-the-phase-1-clinical-trial-of-otx-tic-in-patients-with-glaucoma/2478784/Ocular Therapeutix announced plans to present data on OTX-TIC, a travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension, at the Glaucoma 360 New Horizons Forum being held virtually on January 30. As part of the event, Michael Goldstei